Novo Nordisk Boosts U.S. Obesity Market Strategy Amid Competitor Pressure

Novo Nordisk appoints Poul Weihrauch as a board observer to strengthen its position in the U.S. obesity market, signaling its focus on competitive growth. The company has restructured leadership and expanded sales channels for Wegovy. Meanwhile, FDA approval of Rocket Pharma's gene therapy highlights the ongoing innovation in treatments for ultra-rare diseases.